Johnson and Johnson 2011 Annual Report Download - page 7

Download and view the complete annual report

Please find page 7 of the 2011 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 76

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76

2011 BUSINESS HIGHLIGHTS 5
With these actions and others, our
MD&D business unit has been able to
sustain the No. 1 or No. 2 leadership
positions in 80 percent of our key
platforms while growing or maintaining
share in the majority of these platforms.
We’ve also made some strategic
portfolio decisions in this business
segment, such as refocusing our
cardiovascular business. In 2011,
we exited the drug-eluting stent
business and shifted investments to
higher-growth, higher-need areas like
electrophysiology. These decisions
will help to fund growth potential in
other promising areas. Decisions to
acquire Synthes, Inc. and strengthen
our leadership position in orthopaedics,
as well as our acquisition of SterilMed,
Inc. for its experience in re-processing
surgical instruments, are examples of
how we are continuously looking across
our business for the best long-term
growth opportunities.
CONSUMER
With $14.9 billion in sales in 2011,
our Consumer business segment is
the sixth largest consumer health care
company in the world. Operational sales
declined just under 1 percent, reflecting
the impact of remediation and supply
issues associated with our U.S. over-the-
counter (OTC) business. The decline was
partially offset by solid growth in certain
franchises including Skin Care and Oral
Care, with strong performances from
NEUTROGENA® and the LISTERINE®
Mouthwash brands.
Our Consumer group continued
expanding into emerging markets
with the acquisition of a line of OTC
cough-and-cold brands in Russia from
J.B. Chemicals & Pharmaceuticals
Limited. We also continued to innovate,
introducing NEUTROGENA® Naturals,
AVEENO® SMART ESSENTIALS™,
NICORETTE® QUICKMIST™ and
LISTERINE® ZERO™.
The recovery and remediation of
the McNeil Consumer Healthcare
business continues. The major
commitments to date under the Consent
Decree with the U.S. Food and Drug
Administration have been achieved, and
several products have already returned
to market. Volume will continue to ramp
up, and products will be reintroduced
throughout 2012.
Medical Devices and Diagnostics
Segment Sales
Sales by Major Franchise
(in billions of dollars)
2011 Sales: $25.8
Sales Change
Total: 4.8%
Operational*: 1.7%
Pharmaceutical Segment Sales
Sales by Major Product
(in billions of dollars)
2011 Sales: $24.4
Sales Change
Total: 8.8%
Operational*: 6.2%
Consumer Segment Sales
Sales by Major Franchise
(in billions of dollars)
2011 Sales: $14.9
Sales Change
Total: 2.0%
Operational*: (0.7%)
BABY CARE
$2.4
5.9%
SKIN CARE
$3.7
7.6%
WOUND CARE/
OTHER
$1.0
0.0%
OTC
PHARMACEUTICALS
& NUTRITIONALS
$4.4
(3.2%)
ORAL CARE
$1.6
6.4%
WOMEN’S
HEALTH
$1.8
(2.8%)
* Operational excludes the impact of currency
LEVAQUIN®/FLOXIN®
$0.6
(54.1%)
PREZISTA®
$1.2
41.3%
PROCRIT®/EPREX®
$1.6
(16.1%)
CONCERTA®
$1.3
(3.9%)
ACIPHEX®/PARIET®
$1.0
(3.1%)
RISPERDAL® CONSTA®
$1.6
5.5%
VELCADE®
$1.3
18.0%
OTHER
$10.3
18.2%
REMICADE®
$5.5
19.1%
DEPUY®
$5.8
4.0%
ETHICON
ENDO-SURGERY®
$5.1
6.8%
DIABETES CARE
$2.6
7.4%
ORTHO-CLINICAL
DIAGNOSTICS®
$2.2
5.4%
VISION
CARE
$2.9
8.8%
CARDIOVASCULAR
CARE
$2.3
(10.3%)
ETHICON®
$4.9
8.2%